Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa in anemia of advanced cancer
NCT00269984Phase 2Completed
- Sponsor
- Johnson & Johnson
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 2, randomised, double-blind trial of epoetin alfa in anemia (3 arms), sponsored by Johnson & Johnson. Primary endpoints: Change in Hemoglobin, Change in Hematocrit and 1 more. Status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00269984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269984.